image
Healthcare - Medical - Instruments & Supplies - NASDAQ - US
$ 78.6
1.37 %
$ 18.3 B
Market Cap
23.67
P/E
1. INTRINSIC VALUE

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus.[ Read More ]

The intrinsic value of one HOLX stock under the base case scenario is HIDDEN Compared to the current market price of 78.6 USD, Hologic, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart HOLX

image
FINANCIALS
4.03 B REVENUE
-0.00%
883 M OPERATING INCOME
32.05%
790 M NET INCOME
73.14%
1.29 B OPERATING CASH FLOW
22.26%
-781 M INVESTING CASH FLOW
-413.48%
-1.11 B FINANCING CASH FLOW
-129.43%
988 M REVENUE
-2.32%
230 M OPERATING INCOME
-12.81%
179 M NET INCOME
-8.17%
367 M OPERATING CASH FLOW
-9.56%
-596 M INVESTING CASH FLOW
-1298.36%
-56.8 M FINANCING CASH FLOW
45.28%
Balance Sheet Decomposition Hologic, Inc.
image
Current Assets 3.82 B
Cash & Short-Term Investments 2.33 B
Receivables 600 M
Other Current Assets 889 M
Non-Current Assets 5.33 B
Long-Term Investments 96.4 M
PP&E 538 M
Other Non-Current Assets 4.7 B
Current Liabilities 1.04 B
Accounts Payable 787 M
Short-Term Debt 37.5 M
Other Current Liabilities 213 M
Non-Current Liabilities 2.99 B
Long-Term Debt 2.5 B
Other Non-Current Liabilities 492 M
EFFICIENCY
Earnings Waterfall Hologic, Inc.
image
Revenue 4.03 B
Cost Of Revenue 1.8 B
Gross Profit 2.23 B
Operating Expenses 1.35 B
Operating Income 883 M
Other Expenses 93.1 M
Net Income 790 M
RATIOS
55.28% GROSS MARGIN
55.28%
21.90% OPERATING MARGIN
21.90%
19.59% NET MARGIN
19.59%
15.39% ROE
15.39%
8.62% ROA
8.62%
10.51% ROIC
10.51%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Hologic, Inc.
image
Net Income 790 M
Depreciation & Amortization 309 M
Capital Expenditures -72.4 M
Stock-Based Compensation 82.3 M
Change in Working Capital 0
Others 245 M
Free Cash Flow 1.21 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Hologic, Inc.
image
Wall Street analysts predict an average 1-year price target for HOLX of $79.4 , with forecasts ranging from a low of $33 to a high of $95 .
HOLX Lowest Price Target Wall Street Target
33 USD -58.02%
HOLX Average Price Target Wall Street Target
79.4 USD 1.05%
HOLX Highest Price Target Wall Street Target
95 USD 20.87%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Hologic, Inc.
image
Sold
0-3 MONTHS
4.24 M USD 1
3-6 MONTHS
5.07 M USD 4
6-9 MONTHS
2.04 M USD 3
9-12 MONTHS
6.86 M USD 5
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
2 months ago
Aug 29, 2024
Sell 4.24 M USD
Oberton Karleen Marie
Chief Financial Officer
- 52679
80.557 USD
3 months ago
Aug 06, 2024
Sell 39.6 K USD
Schnittker Brandon
Div. President, GYN Surgical
- 476
83.108 USD
3 months ago
Aug 01, 2024
Sell 418 K USD
COHN BENJAMIN JORDAN
Principal Accounting Officer
- 5093
81.989 USD
3 months ago
Jul 30, 2024
Sell 615 K USD
MACMILLAN STEPHEN P
Chairman, President and CEO
- 7634
80.6 USD
3 months ago
Jul 30, 2024
Sell 1.32 M USD
MACMILLAN STEPHEN P
Chairman, President and CEO
- 16177
81.44 USD
3 months ago
Jul 30, 2024
Sell 1.67 M USD
MACMILLAN STEPHEN P
Chairman, President and CEO
- 20228
82.32 USD
4 months ago
Jul 17, 2024
Sell 294 K USD
MACMILLAN STEPHEN P
Chairman, President and CEO
- 3672
80.126 USD
4 months ago
Jul 17, 2024
Sell 719 K USD
Stamoulis Christiana
Director
- 9039
79.5 USD
8 months ago
Mar 14, 2024
Sell 1.24 M USD
GARRETT SCOTT T
Director
- 16441
75.5 USD
8 months ago
Mar 08, 2024
Sell 112 K USD
Dockendorff Charles J
Director
- 1465
76.21 USD
8 months ago
Mar 08, 2024
Sell 691 K USD
CRAWFORD SALLY
Director
- 9039
76.403 USD
9 months ago
Jan 29, 2024
Sell 1.12 M USD
Oberton Karleen Marie
Chief Financial Officer
- 14940
75 USD
10 months ago
Jan 02, 2024
Sell 1.15 M USD
Dockendorff Charles J
Director
- 16017
72 USD
11 months ago
Dec 11, 2023
Sell 687 K USD
GARRETT SCOTT T
Director
- 10000
68.7116 USD
11 months ago
Nov 29, 2023
Sell 3.36 M USD
MACMILLAN STEPHEN P
Chairman, President and CEO
- 47711
70.407 USD
11 months ago
Nov 21, 2023
Sell 539 K USD
Mitchell Essex D
Div. President, GYN Surgical
- 7500
71.852 USD
1 year ago
Jun 15, 2023
Sell 797 K USD
GARRETT SCOTT T
Director
- 10000
79.724 USD
1 year ago
May 05, 2023
Sell 200 K USD
Mitchell Essex D
Div. President, GYN Surgical
- 2390
83.7302 USD
1 year ago
Feb 07, 2023
Sell 778 K USD
COHN BENJAMIN JORDAN
Principal Accounting Officer
- 9128
85.281 USD
1 year ago
Dec 14, 2022
Sell 126 K USD
Hellmann Elisabeth A
SVP, Human Resources
- 1649
76.4 USD
1 year ago
Nov 30, 2022
Sell 1.58 M USD
MACMILLAN STEPHEN P
Chairman, President and CEO
- 20999
75.434 USD
1 year ago
Nov 30, 2022
Sell 950 K USD
MACMILLAN STEPHEN P
Chairman, President and CEO
- 12501
76.02 USD
2 years ago
Nov 15, 2022
Sell 941 K USD
Thornal Kevin R
Group Pres, Global Diagnostics
- 12490
75.301 USD
2 years ago
Nov 14, 2022
Sell 1.8 M USD
Griffin John M.
General Counsel
- 23634
76.073 USD
2 years ago
Nov 14, 2022
Sell 250 K USD
Griffin John M.
General Counsel
- 3268
76.493 USD
2 years ago
Nov 11, 2022
Sell 3.97 M USD
MACMILLAN STEPHEN P
Chairman, President and CEO
- 52529
75.569 USD
2 years ago
Nov 11, 2022
Sell 3.26 M USD
MACMILLAN STEPHEN P
Chairman, President and CEO
- 42893
75.94 USD
2 years ago
Nov 01, 2022
Sell 1.05 M USD
Oberton Karleen Marie
Chief Financial Officer
- 14545
72.5 USD
2 years ago
May 17, 2022
Sell 512 K USD
Verstreken Jan
Group President, International
- 6500
78.795 USD
2 years ago
May 17, 2022
Sell 303 K USD
COHN BENJAMIN JORDAN
Principal Accounting Officer
- 3844
78.754 USD
2 years ago
May 13, 2022
Sell 242 K USD
COHN BENJAMIN JORDAN
Principal Accounting Officer
- 3210
75.493 USD
2 years ago
May 13, 2022
Sell 290 K USD
COHN BENJAMIN JORDAN
Principal Accounting Officer
- 3842
75.49 USD
2 years ago
May 03, 2022
Sell 162 K USD
COHN BENJAMIN JORDAN
Principal Accounting Officer
- 2178
74.18 USD
2 years ago
Feb 24, 2022
Sell 155 K USD
Daugherty Sean S.
Group President, BSH & Surg.
- 2179
71.141 USD
2 years ago
Nov 19, 2021
Sell 195 K USD
COHN BENJAMIN JORDAN
Principal Accounting Officer
- 2570
75.794 USD
3 years ago
Aug 10, 2021
Sell 387 K USD
COHN BENJAMIN JORDAN
Principal Accounting Officer
- 5000
77.485 USD
3 years ago
Aug 09, 2021
Sell 2.02 M USD
Griffin John M.
General Counsel
- 26683
75.62 USD
3 years ago
May 10, 2021
Sell 260 K USD
Daugherty Sean S.
Group President, BSH & Surg.
- 4001
65.021 USD
3 years ago
Feb 05, 2021
Sell 513 K USD
Bebo Allison P
SVP, Human Resources
- 6100
84.062 USD
3 years ago
Feb 04, 2021
Sell 708 K USD
COHN BENJAMIN JORDAN
Principal Accounting Officer
- 8396
84.31 USD
3 years ago
Dec 10, 2020
Sell 683 K USD
Thornal Kevin R
Div. President, Diagnostics
- 9236
73.994 USD
3 years ago
Dec 10, 2020
Sell 565 K USD
Thornal Kevin R
Div. President, Diagnostics
- 7633
73.995 USD
3 years ago
Dec 10, 2020
Sell 109 K USD
COHN BENJAMIN JORDAN
Principal Accounting Officer
- 1477
73.635 USD
4 years ago
Nov 18, 2020
Sell 801 K USD
Griffin John M.
General Counsel
- 11321
70.796 USD
4 years ago
Nov 18, 2020
Sell 826 K USD
Griffin John M.
General Counsel
- 11579
71.354 USD
4 years ago
Nov 17, 2020
Sell 363 K USD
COHN BENJAMIN JORDAN
Principal Accounting Officer
- 5000
72.58 USD
4 years ago
Nov 12, 2020
Sell 462 K USD
COHN BENJAMIN JORDAN
Principal Accounting Officer
- 6542
70.597 USD
4 years ago
Nov 04, 2020
Sell 825 K USD
Stamoulis Christiana
Director
- 11146
74 USD
4 years ago
Sep 21, 2020
Sell 938 K USD
Oberton Karleen Marie
Chief Financial Officer
- 15000
62.5 USD
4 years ago
Aug 03, 2020
Sell 26.3 K USD
COHN BENJAMIN JORDAN
Principal Accounting Officer
- 369
71.22 USD
4 years ago
Aug 03, 2020
Sell 138 K USD
COHN BENJAMIN JORDAN
Principal Accounting Officer
- 1938
71.27 USD
4 years ago
Aug 03, 2020
Sell 186 K USD
COHN BENJAMIN JORDAN
Principal Accounting Officer
- 2617
71.23 USD
4 years ago
Jun 30, 2020
Sell 567 K USD
Valenti Peter J. III
Division Pres., Breast Health
- 10493
54.07 USD
4 years ago
May 22, 2020
Sell 544 K USD
Valenti Peter J. III
Division Pres., Breast Health
- 10493
51.823 USD
4 years ago
May 22, 2020
Sell 1.66 M USD
CRAWFORD SALLY
Director
- 31950
51.99 USD
4 years ago
May 15, 2020
Sell 715 K USD
Thornal Kevin R
Div. President, Diagnostics
- 13888
51.514 USD
4 years ago
May 13, 2020
Sell 9.74 M USD
MACMILLAN STEPHEN P
Chairman, President and CEO
- 190996
50.971 USD
4 years ago
Apr 28, 2020
Sell 107 K USD
Griffin John M.
General Counsel
- 2133
50 USD
4 years ago
Mar 09, 2020
Sell 144 K USD
CRAWFORD SALLY
Director
- 3300
43.574 USD
4 years ago
Mar 09, 2020
Sell 348 K USD
CRAWFORD SALLY
Director
- 7846
44.293 USD
4 years ago
Feb 03, 2020
Sell 10.4 M USD
MACMILLAN STEPHEN P
Chairman, President and CEO
- 194396
53.536 USD
4 years ago
Jan 13, 2020
Sell 452 K USD
Griffin John M.
General Counsel
- 8532
52.969 USD
4 years ago
Jan 13, 2020
Sell 585 K USD
Griffin John M.
General Counsel
- 11092
52.777 USD
4 years ago
Jan 02, 2020
Sell 536 K USD
Oberton Karleen Marie
Chief Financial Officer
- 10375
51.662 USD
4 years ago
Jan 02, 2020
Sell 310 K USD
Oberton Karleen Marie
Chief Financial Officer
- 5973
51.849 USD
4 years ago
Dec 04, 2019
Sell 228 K USD
COHN BENJAMIN JORDAN
Principal Accounting Officer
- 4379
52.118 USD
4 years ago
Nov 22, 2019
Sell 220 K USD
COHN BENJAMIN JORDAN
Principal Accounting Officer
- 4400
50.091 USD
4 years ago
Nov 22, 2019
Sell 612 K USD
Stamoulis Christiana
Director
- 12306
49.75 USD
5 years ago
Nov 11, 2019
Sell 3.06 M USD
MACMILLAN STEPHEN P
Chairman, President and CEO
- 67440
45.444 USD
5 years ago
Nov 11, 2019
Sell 5.86 M USD
MACMILLAN STEPHEN P
Chairman, President and CEO
- 126956
46.157 USD
5 years ago
Sep 03, 2019
Sell 382 K USD
Valenti Peter J. III
Division Pres., Breast Health
- 7766
49.14 USD
5 years ago
Aug 05, 2019
Sell 5.44 M USD
MACMILLAN STEPHEN P
Chairman, President and CEO
- 112451
48.413 USD
5 years ago
Aug 05, 2019
Sell 4.04 M USD
MACMILLAN STEPHEN P
Chairman, President and CEO
- 81945
49.264 USD
5 years ago
Jun 03, 2019
Sell 200 K USD
Valenti Peter J. III
Division Pres., Breast Health
- 4545
44.07 USD
5 years ago
Mar 18, 2019
Sell 586 K USD
CRAWFORD SALLY
Director
- 12306
47.61 USD
5 years ago
Mar 11, 2019
Sell 319 K USD
COHN BENJAMIN JORDAN
Principal Accounting Officer
- 6830
46.7 USD
7. News
Should You Retain Hologic Stock in Your Portfolio Now? HOLX's strength in the Molecular Diagnostics wing instills optimism among investors. Yet, macro woes and currency impacts raise concerns. zacks.com - 2 days ago
Hologic to Webcast Presentations at Upcoming Investor Conferences MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #Citi--Hologic to Webcast Presentations at Upcoming Investor Conferences. businesswire.com - 3 days ago
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects. zacks.com - 1 week ago
Hologic Post Q4 Earnings Miss: Time to Buy, Hold or Sell the Stock? Despite the recent earnings miss, Hologic's portfolio strength and capital allocation strategy can be appealing to investors. zacks.com - 1 week ago
Hologic Q4 Earnings Lag, Revenues Top, Stock Down in Aftermarket HOLX's fiscal 2024 fourth-quarter results underscore the durable growth of its businesses. zacks.com - 1 week ago
Hologic, Inc. (HOLX) Q4 2024 Earnings Call Transcript Hologic, Inc. (NASDAQ:HOLX ) Q4 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Ryan Simon - Vice President, Investor Relations Stephen MacMillan - Chairman, President & Chief Executive Officer Essex Mitchell - Chief Operating Officer Karleen Oberton - Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Jack Meehan - Nephron Research Anthony Petrone - Mizuho Group Vijay Kumar - Evercore ISI Casey Woodring - JPMorgan Mike Matson - Needham & Company Navann Ty - BNP Paribas Ricardo Moreno - RBC Capital Markets Maggie Wilmouth - William Blair Andrew Cooper - Raymond James Operator Good afternoon, and welcome to the Hologic's Fourth Quarter Fiscal 2024 Earnings Conference Call. My name is Shelly, and I am your operator for today's call. seekingalpha.com - 1 week ago
Hologic (HOLX) Reports Q4 Earnings: What Key Metrics Have to Say While the top- and bottom-line numbers for Hologic (HOLX) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com - 1 week ago
Hologic (HOLX) Q4 Earnings Miss Estimates Hologic (HOLX) came out with quarterly earnings of $1.01 per share, missing the Zacks Consensus Estimate of $1.02 per share. This compares to earnings of $0.89 per share a year ago. zacks.com - 1 week ago
Unlocking Q4 Potential of Hologic (HOLX): Exploring Wall Street Estimates for Key Metrics Evaluate the expected performance of Hologic (HOLX) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight. zacks.com - 2 weeks ago
Hologic (HOLX) Stock Falls Amid Market Uptick: What Investors Need to Know In the latest trading session, Hologic (HOLX) closed at $80.46, marking a -0.46% move from the previous day. zacks.com - 2 weeks ago
Hologic (HOLX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release Hologic (HOLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 2 weeks ago
Will Non-COVID-19 Diagnostics Sales Drive Hologic's Q4 Earnings? HOLX's fiscal 2024 fourth-quarter results are expected to reflect a solid performance of the Diagnostics business, led by the base Molecular franchise. zacks.com - 3 weeks ago
8. Profile Summary

Hologic, Inc. HOLX

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 18.3 B
Dividend Yield 0.00%
Description Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
Contact 250 Campus Drive, Marlborough, MA, 01752 https://www.hologic.com
IPO Date March 1, 1990
Employees 6990
Officers Mr. Ryan M. Simon Vice President of Investor Relations Mr. Jan Verstreken Group President of International Mr. Paul Malenchini Chief Information Officer Mr. Scott Christensen Senior Vice President of Global Supply Chain, Quality & Regulatory Mr. Essex D. Mitchell Chief Operating Officer Dr. Jennifer M. Schneiders Ph.D. President of Diagnostics Solutions Ms. Diana De Walt SPHR Senior Vice President of Global Human Resources Mr. Stephen P. MacMillan Chairman, Chief Executive Officer & President Ms. Monica Aguirre Berthelot Vice President & Chief of Staff Mr. Erik S. Anderson Division President of Breast & Skeletal Health Solutions